# Endometriosis FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/endometriosis

> 2 upcoming FDA catalysts in endometriosis: Orilissa (elagolix sodium, ABBV) on July 2027 (primary completion); Orilissa (elagolix sodium, ABBV) on Jul to Oct 2027 (topline data readout).

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| May 28, 2025 | [OG-6219 primary completion](https://sec-api.dev/pdufa/og-6219) | OGN | Endometriosis | completed | "NCT05560646 (A Study to Investigate Efficacy and Safety of OG-6219 BID in 3 Dose Levels Compared With Placebo in Participants Aged 18 to 49 With Moderate to Severe Endometriosis-related Pain): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-05-28 (ACTUAL); Lead Sponsor Organon and Co; Results First Posted 2026-05-08." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05560646)) |
| May 8, 2026 | [OG-6219 topline data readout](https://sec-api.dev/pdufa/og-6219) | OGN | Endometriosis | completed | "NCT05560646 (A Study to Investigate Efficacy and Safety of OG-6219 BID in 3 Dose Levels Compared With Placebo in Participants Aged 18 to 49 With Moderate to Severe Endometriosis-related Pain): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-05-28 (ACTUAL); Lead Sponsor Organon and Co; Results First Posted 2026-05-08." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05560646?tab=results)) |
| July 2027 | [Orilissa (elagolix sodium) primary completion](https://sec-api.dev/pdufa/elagolix) | ABBV | Endometriosis | scheduled | "NCT04333576 (Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules/Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-07 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04333576)) |
| Jul to Oct 2027 | [Orilissa (elagolix sodium) topline data readout](https://sec-api.dev/pdufa/elagolix) | ABBV | Endometriosis | scheduled | "NCT04333576 (Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules/Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-07 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04333576)) |

## Drugs

- [OG-6219](https://sec-api.dev/pdufa/og-6219) (OGN)
- [Orilissa (elagolix sodium)](https://sec-api.dev/pdufa/elagolix) (ABBV)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/endometriosis.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Endometriosis FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/endometriosis

```bibtex
@misc{secapidev_indications_endometriosis_20261116,
  title        = {Endometriosis FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/endometriosis}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_endometriosis_20261116","title":"Endometriosis FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/endometriosis","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
